Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
NEW YORK, Oct. 14, 2014 /PRNewswire/ -- Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, "Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
The PCSK9 field is flush with new mAbs. In its current state, GlobalData expects that alirocumab will be the second-to-market PCSK9, following Amgen's PCSK9 mAb, evolocumab. GlobalData anticipates that Pfizer's PCSK9, bococizumab, which is entering Phase III later than these Sanofi/Regeneron and Amgen mAbs, will be third to market. These companies are designing complex, outcomes-based, Phase III clinical trials in an effort to show that the PCSK9 mAbs can effectively reduce the risk of occurrence of cardiovascular events in addition to reducing plasma LDL-C levels.
Scope
- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Read the full report: http://www.reportlinker.com/p02370544-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article